362 related articles for article (PubMed ID: 22277104)
21. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Tonelli M; Garg AX; Pellegrini F; Ravani P; Jardine M; Perkovic V; Graziano G; McGee R; Nicolucci A; Tognoni G; Strippoli GF
Ann Intern Med; 2010 Jul; 153(1):23-33. PubMed ID: 20439566
[TBL] [Abstract][Full Text] [Related]
22. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Smith RE; Aapro MS; Ludwig H; Pintér T; Smakal M; Ciuleanu TE; Chen L; Lillie T; Glaspy JA
J Clin Oncol; 2008 Mar; 26(7):1040-50. PubMed ID: 18227526
[TBL] [Abstract][Full Text] [Related]
23. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial.
Grote T; Yeilding AL; Castillo R; Butler D; Fishkin E; Henry DH; DeLeo M; Fink K; Sullivan DJ
J Clin Oncol; 2005 Dec; 23(36):9377-86. PubMed ID: 16361638
[TBL] [Abstract][Full Text] [Related]
25. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
26. Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis-stimulating agents and transfusion in patients with chemotherapy-induced anaemia.
Hollingsworth K; Romney MC; Crawford A; McAna J
J Clin Pharm Ther; 2015 Jun; 40(3):299-303. PubMed ID: 25893427
[TBL] [Abstract][Full Text] [Related]
27. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.
Bohlius J; Schmidlin K; Brillant C; Schwarzer G; Trelle S; Seidenfeld J; Zwahlen M; Clarke MJ; Weingart O; Kluge S; Piper M; Napoli M; Rades D; Steensma D; Djulbegovic B; Fey MF; Ray-Coquard I; Moebus V; Thomas G; Untch M; Schumacher M; Egger M; Engert A
Cochrane Database Syst Rev; 2009 Jul; 2009(3):CD007303. PubMed ID: 19588423
[TBL] [Abstract][Full Text] [Related]
28. Impact of erythropoiesis-stimulating agent prescribing at an Asian cancer center, after release of safety advisories.
Chan Q; Chan A
J Oncol Pharm Pract; 2011 Dec; 17(4):350-9. PubMed ID: 20659968
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials.
Ohashi Y; Uemura Y; Fujisaka Y; Sugiyama T; Ohmatsu H; Katsumata N; Okamoto R; Saijo N; Hotta T
Cancer Sci; 2013 Apr; 104(4):481-5. PubMed ID: 23331490
[TBL] [Abstract][Full Text] [Related]
30. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
Wauters I; Vansteenkiste J
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
[TBL] [Abstract][Full Text] [Related]
31. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
32. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
33. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
[TBL] [Abstract][Full Text] [Related]
34. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials.
Zhan P; Wang Q; Qian Q; Yu LK
Chin Clin Oncol; 2012 Dec; 1(2):19. PubMed ID: 25841397
[TBL] [Abstract][Full Text] [Related]
35. Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits.
Hill JW; Shreay S; McGarvey N; De AP; Hess GP; Corey-Lisle PK
Support Care Cancer; 2013 Nov; 21(11):2957-65. PubMed ID: 23756616
[TBL] [Abstract][Full Text] [Related]
36. Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey.
Ray-Coquard I; Morère JF; Scotté F; Cals L; Antoine EC
Adv Ther; 2012 Feb; 29(2):124-33. PubMed ID: 22314432
[TBL] [Abstract][Full Text] [Related]
37. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
Wright JR; Ung YC; Julian JA; Pritchard KI; Whelan TJ; Smith C; Szechtman B; Roa W; Mulroy L; Rudinskas L; Gagnon B; Okawara GS; Levine MN
J Clin Oncol; 2007 Mar; 25(9):1027-32. PubMed ID: 17312332
[TBL] [Abstract][Full Text] [Related]
38. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
Bohlius J; Schmidlin K; Brillant C; Schwarzer G; Trelle S; Seidenfeld J; Zwahlen M; Clarke M; Weingart O; Kluge S; Piper M; Rades D; Steensma DP; Djulbegovic B; Fey MF; Ray-Coquard I; Machtay M; Moebus V; Thomas G; Untch M; Schumacher M; Egger M; Engert A
Lancet; 2009 May; 373(9674):1532-42. PubMed ID: 19410717
[TBL] [Abstract][Full Text] [Related]
39. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
Bennett CL; Silver SM; Djulbegovic B; Samaras AT; Blau CA; Gleason KJ; Barnato SE; Elverman KM; Courtney DM; McKoy JM; Edwards BJ; Tigue CC; Raisch DW; Yarnold PR; Dorr DA; Kuzel TM; Tallman MS; Trifilio SM; West DP; Lai SY; Henke M
JAMA; 2008 Feb; 299(8):914-24. PubMed ID: 18314434
[TBL] [Abstract][Full Text] [Related]
40. Management of anemia in cancer patients.
Calabrich A; Katz A
Future Oncol; 2011 Apr; 7(4):507-17. PubMed ID: 21463140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
